Cell Genesys to Present at the NewsMakers in the Biotech Industry Conference

SOUTH SAN FRANCISCO, Calif.--(Business Wire)--
Cell Genesys, Inc. (Nasdaq:CEGE) today announced that Sharon E.
Tetlow, senior vice president and chief financial officer of Cell
Genesys, will present a company update at the NewsMakers in the
Biotech Industry Conference in New York City on Thursday, September 4,
2008, at 10:30 a.m. ET.

A live audio webcast of the presentation will be accessible
through the Investor Relations section of the Cell Genesys website,
www.cellgenesys.com. If you are unable to listen to the live webcast,
it will be archived on the site for at least 72 hours following the
presentation. To access the replay, go to the Investor Relations
section of the website.

Cell Genesys is focused on the development and commercialization
of novel biological therapies for patients with cancer. The company is
currently pursuing two clinical stage product platforms -- GVAX(R)
cancer immunotherapies and oncolytic virus therapies. Ongoing clinical
trials include a Phase 3 trial of GVAX immunotherapy for prostate
cancer, which is being developed in partnership with Takeda
Pharmaceutical Company Limited, Phase 2 trials of GVAX immunotherapies
for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070
oncolytic virus therapy for bladder cancer. Cell Genesys continues to
hold an equity interest in its former subsidiary, Ceregene, Inc.,
which is developing gene therapies for neurodegenerative disorders.
Cell Genesys is headquartered in South San Francisco, CA and has its
principal manufacturing operation in Hayward, CA. For additional
information, please visit the company's website at
www.cellgenesys.com.

Cell Genesys, Inc.
Susan Ferris, 650-266-3200 (Investor Relations)

Copyright Business Wire 2008